Company Profile

Natural Pharmacia International Inc (AKA: NPI)
Profile last edited on: 1/17/2024      CAGE: 36QQ6      UEI: S1XLM7VGK1W6

Business Identifier: Botanical drugs and herbal supplements based on Traditional Chinese Medicine (TCM)
Year Founded
1991
First Award
1994
Latest Award
2018
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

121 Middlesex Turnpike Unit 5
Burlington, MA 01803
   (781) 272-6888
   tlee@natural-pharma.com
   www.natural-pharma.com
Location: Single
Congr. District: 06
County: Middlesex

Public Profile

Natural Pharmacia International (NPI) Inc develops botanical drugs and herbal supplements based on Tradtional Chinese Medicine (TCM). The firm was established in 1991 by Dr. David Y. Lee, a Professor at Harvard Medical School and Director of the Natural Products Lab at Harvard Mclean Hospital, and well known player in the field. With TCM practiced for thousands of years, NPI is structured around culling through the wisdom of TCM, validating and further developing selected gems with modern technology and methodology with the objective being to achieve FDA approved botanical drugs. Arobust pipeline of TCM-based botanical drugs are already in clinical trials. NPI also leverages its first-class discovery and development capabilities to identify and develop the bioactive single-molecules responsible for the therapeutic effects of certain herbs.AThe firm is already marke ing certain herbal products, with safety and efficacy in mind, as functional dietary supplements. The

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2018 2 NIH $1,154,747
Project Title: Development of Alkontrol Herbal for Treating Alcohol Abuse
2018 2 NIH $999,146
Project Title: Preclinical Validation of Novel High Affinity D2 Receptor Agonists for PET Neuroimaging
2014 1 NIH $148,426
Project Title: Development of a Tritiated Agonist Radioligand for the D2 Receptor
2008 2 NIH $3,749,319
Project Title: Development of Puerarin to Reduce Alcohol Drinking
2004 2 NIH $1,800,182
Project Title: Development of Standardized Milk Thistle Product

Key People / Management

  Tina Lee -- President

  Qi-Cheng Fang

  David Lee Yue-Wei -- Founder

  Haixia Li

  Yanze Liu

  Yue-Hu Pei

  James A Raleigh

Company News

There are no news available.